30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: NuVasive

$169.2MM, +14% (Ex-U.S. +31%)

  • U.S. lumbar +12%, supported by Precept, MAS, PLIF, XLIF
  • U.S. biologics +11%, driven by strong lumbar procedure volume
  • U.S. cervical +27%
  • U.S. monitoring -4%, affected by reimbursement challenges


  • Raising 2013 guidance from $655MM to $670MM, motivated by U.S. lumbar and biologics growth; Japan should reach expected $8MM in 2013
  • Believes that the spine market is stabilizing; expects U.S. growth to be flat into 2014
  • Increasing number of U.S. sales reps
  • Observed anti-physician owned distributorship (POD) policies in “several hospital systems” (and has been asked whether NuVasive is a POD)
  • Introduced Bendini Spinal Rod Bending system for pre-op computer-assisted customization and the XLIF Decade plate for lateral spinal stabilization
  • Medical device tax at ~$1.2MM for the quarter